Plain-English translation of NCT06232265 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether a measurement called LIRAscore—found in tissue samples—can predict whether immunotherapy will work well for your lung cancer. This is an observational study, meaning researchers will follow your progress and collect information rather than assigning you to different treatment groups. The goal is to help doctors better understand which patients will benefit most from immunotherapy, either alone or combined with chemotherapy.
Currently, doctors don't have a reliable way to predict which lung cancer patients will respond well to immunotherapy before starting treatment. This study aims to develop a simple blood test that could help identify who will benefit most, potentially sparing some patients from ineffective treatments and their side effects.
You likely qualify if…
You likely don't qualify if…
You would continue with your regular cancer treatment (immunotherapy alone or with chemotherapy) as recommended by your doctor. Researchers would collect a small tissue sample from your diagnostic biopsy and track your response to treatment over time using standard cancer follow-up visits and scans. The study involves monitoring how well the treatment works and comparing that to your LIRAscore results to see if the blood marker accurately predicted your outcome.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Sponsor
Nanfang Hospital, Southern Medical University
Enrollment target
~108 participants
Started
September 2023
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in January 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wangjun Liao, MD, PhD
Nanfang Hospital, Southern Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.